Selvigaltin
Selvigaltin is the first small-molecule, orally delivered galectin-3 inhibitor to be discovered. It is developed by Galecto Biotech, which is testing the molecule to see if it reduces decompensated cirrhosis and resistance to checkpoint inhibitors.